Huagongshe화공사 화학 정보 인쇄 보고서 · 연구 참고용
HRID 256생성일: 2026년 10월 23일
3-Methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)aniline → (R)-2-(8-(3-Methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenylamino)-2-phenyl-2,3-dihydropyrido[3,2-f][1,4]oxazepin-4(5H)-yl)ethanol
https://huagongshe.com/ko/reaction/256
참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|
| 반응물 | 3-Methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)aniline | HCID 59577818 | — |
| 반응물 | (R)-2-(8-chloro-2-phenyl-2,3-dihydropyrido[3,2-f][1,4]oxazepin-4(5H)-yl)ethanol | HCID 59577824 | — |
| 시약 | Cesium carbonate | HCID 10796 | — |
| 촉매 | 2-(Dicyclohexylphosphino)biphenyl | HCID 2734216 | — |
| 촉매 | Palladium (II) acetate | HCID 4144353 | — |
| 용매 | 1,2-Dimethoxyethane | HCID 8071 | — |
| 생성물 | (R)-2-(8-(3-Methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenylamino)-2-phenyl-2,3-dihydropyrido[3,2-f][1,4]oxazepin-4(5H)-yl)ethanol | HCID 49819229 | 21.28% |
반응 단계
3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)aniline (67.0 mg, 0.33 mmol), (R)-2-(8-chloro-2-phenyl-2,3-dihydropyrido[3,2-f][1,4]oxazepin-4(5H)-yl)ethanol (100 mg, 0.33 mmol), Palladium acetate (7.37 mg, 0.03 mmol), 2-(Dicyclohexylphosphino)biphenyl (11.50 mg, 0.03 mmol) and Cesium carbonate (321 mg, 0.98 mmol) were added to a microwave vial. 1,2-dimethoxyethane (2 mL) was added. The reaction mixture was flushed with argon and the mixture was run in a microwave for 60 minutes at 100°C. No product was observed. Additional catalyst and ligand were added and the reaction was run 1h @ 100°C. Still no reaction occurred. EtOH (0.500 mL) was added and another h @ 100°C was executed. Full conversion into product was observed. The solids were filtered off and the solvent was concentrated. The crude product was purified twice on Si. 20-80% MeOH in DCM. Yield: (R)-2-(8-(3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenylamino)-2-phenyl-2,3-dihydropyrido[3,2-f][1,4]oxazepin-4(5H)-yl)ethanol (33.0 mg, 21.28 %).
출처 및 근거
| 출처 데이터셋 | 750 AstraZeneca ELN dataset |
|---|
| ORD ID | ord-d3bf2a42ca064635a16f6a54a057bf59 |
|---|
| 출처 메모 | 750 AstraZeneca ELN dataset |
|---|